Orphazyme (STRAP.CO) Stock Analysis & AI Equity Report
Orphazyme (STRAP.CO) overview
Orphazyme (STRAP.CO) stock analysis and AI equity research. For the latest completed financial year, 2023, Orphazyme reported revenue of DKK 0m and operating profit of DKK -0.0m; the year-end share price was N/A and market capitalisation was N/A. Orphazyme is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Orphazyme's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-08-29. Data will be refreshed during report generation.
About Orphazyme
Orphazyme A/S is a Danish biopharmaceutical company that developed heat-shock-protein-based therapies for rare neurodegenerative and lysosomal storage diseases, including arimoclomol as its lead candidate. In 2022, it sold substantially all assets and business activities, and current company materials emphasize restructuring and limited corporate activities rather than active drug development.
Generate the Orphazyme report
Orphazyme is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Orphazyme and represent the latest completed financial year (2023). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.